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Nowadays many companies typically spend 
large amounts of money on R&D. For large 
companies R&D expenditures constitute 
a  large share of their annual revenue. For 
example, in 2016 Intel spent on R&D ac-
tivities approximately 22% of its revenue, 
while for Bristol-Myers Squibb the corre-
sponding ratio is 36%. Another distinctive 
feature of corporate R&D spending is that 
industrial leaders are engaged in R&D ac-
tivities on a  constant basis. Indeed, nine 
companies (Volkswagen, Toyota, Samsung, 
Intel, Microsoft, Roche, Novartis, Pfizer, 
J&J) are in the list of top 20 world R&D 
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spenders for ten years straight [Jaruzelski, 
Schwartz, Staack, 2015].
The analysis of statistical data presented 
in [Jaruzelski, Schwartz, Staack, 2015] re-
veals that the amount of R&D spending is 
significantly industry-dependent. Companies 
with the most significant R&D expenditures 
belong to the computing and electronics, 
healthcare, and auto sectors. Moreover, even 
within a single industry the amount of R&D 
investments can vary from company to com-
pany. For example, in 2015 Intel and Apple, 
both included into the computing and elec-
tronics industry, demonstrated different 
numbers in terms of R&D spending: Intel 
spent 20.6% in 2015 on R&D, while Apple 
spent 3.3%.
Overall, these large costs should look un-
favorable to companies’ shareholders because 
R&D spending itself does not create value. 
In other words, R&D spending should in 
theory have negative net present value be-
cause, being fixed nonmanufacturing costs, 
these expenditures lower profits and as a re-
sult should eventually undermine companies’ 
market capitalization. Nevertheless, the 
analysis of business practice reveal that R&D 
spending increases companies’ financial re-
sults in the long run and therefore these 
costs are perceived favorably by shareholders. 
For example, the Golden Sachs report reveals 
strong positive relation between R&D spend-
ing, sales growth and stock returns for eight 
years to 2012 for the companies of technol-
ogy, Internet, and biotech sectors. The aca-
demic research brought similar results. For 
example, [Ding, Stolowy, Tenenhaus, 2007] 
using the cross-country sample of com-
panies from Canada, Germany, Japan, 
Switzerland, the UK, and the USA show 
that R&D expenditures contribute to future 
earnings, although the amount of this con-
tribution varies between countries. On the 
sample of OECD countries [Aydin, Alrajhi, 
Jouini, 2018] reveal that R&D expenditures 
is one of the drivers of total economic pro-
ductivity.
Apparently, potential positive impact of 
R&D spending on future earnings is due to 
the fact that the results of R&D activities 
in the case of their successful implementa-
tion can provide companies with capabili-
ties to produce goods using some advanced 
technology or to produce fundamentally new 
products. In order to exploit these benefits, 
however, companies need to invest in manu-
facturing of these products or in change of 
technologies. R&D activities provide the jus-
tification for such investments or, in other 
words, without R&D these investments can 
hardly be possible. One of the main research 
questions is to assess the feasible amount 
of R&D expenditures.
The real options approach is one of the 
commonly used methods to assess R&D 
spending of companies. Here a  company 
faces many kinds of uncertainty. The key 
idea is that R&D spending can be considered 
as a  payment for acquiring the exclusive 
right to make investments in real assets 
in the future. Such an approach explicitly 
allows the treatment of R&D spending as 
a  real option.
Despite the fact that the real option ap-
proach is frequently applied to assessing 
R&D projects, as far as we know, there is 
a  lack of studies that directly apply this 
approach to explain industrial differences 
of companies in R&D spending. Thus, the 
goal of our paper is to propose a  model to 
assess the industrial R&D intensity by treat-
ing R&D expenditures as the value of a re-
al option. 
The structure of the paper is as follows. 
Section  1 introduces general framework 
on real R&D options. Section  2 presents 
the problem and assumptions used in our 
original research model. Section 3 provides 
the detailed description of the model at 
the company level whereas Section  4 does 
the same at industry level in the terms of 
R&D intensity indicator. Main formulas 
(6) and (12) for R&D expenditure are de-
rived. Section 5 is devoted to some empiri-
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cal validation of these formulas. Section 6 
concludes and outlines some directions for 
further research.
1. Real R&D options
In financial literature extensive elabora-
tion of real options theory has started in 
1980s  with introduction of powerful re-
search tools for their use in various areas 
of finance and strategic management. The 
main contributions include understanding 
of valuation and decision making in uncer-
tain world, which takes into account irre-
versibility of investments and flexibility of 
managerial decisions. The concept of risk-
neutral valuation or, better to say, that of 
decision making in risk-neutral environ-
ment, has been in the center of techniques 
starting from the seminal Black–Scholes 
contribution (see [Hull, 2012]  for the his-
tory). This technique is the main tool in 
construction of our model. 
During 1990s  a bulk of literature with 
applications of real options to various areas 
of management has appeared. Among those 
were strategic management, IT investment 
and R&D investment. After the special issue 
in R&D Management journal (see [Paxson, 
2001] and other papers of the issue) and 
[Newton, Paxson, Widdicks, 2004] the notion 
of real R&D option has been widely accepted. 
Actually the variety of understandings of 
R&D investments and associated options 
thereof is almost inexhaustible. [Teece, 2018] 
emphasizes many different types of R&D 
projects. In [Childs, Triantis, 1999] authors 
show many different R&D investment strat-
egies that provide important flexibility for 
the projects (usually multi-stage analysis is 
involved). In [Oriani, Sobrero, 2008]  they 
analyze different types of uncertainty (mar-
ket vs technology). Paper [Cuervo-Cazurra, 
Un, 2010] relates R&D investments of a com-
pany with its knowledge resources. Authors 
[Chakravarty, Grewal, 2011] analyze the be-
havior of managers in response to stock mar-
ket reaction on R&D investments. This issue 
is related both to growth options and mar-
keting budget. 
We also should mention that the major-
ity of papers are devoted to the use of real 
options methodology for companies from 
specific industries. For instance, [Choi, 
Kwak, Yoo, 2016] apply real options ap-
proach to the deep seabed manganese nodule 
mining projects. Their results reveal that 
the project, indeed, has economic potential 
that was not captured by traditional valu-
ation methods such as discounted cash flow 
(DCF) approach. In [Managi, Zhang, Horie, 
2016] scholars use real option approach to 
account for different types of uncertainty 
in the environmental project. [Kellogg, 
Charnes, 2000]  discuss the applicability of 
real options approach to a company of phar-
maceutical industry. [Pennings, Sereno, 
2011] continues this line of applications. 
Another line of research papers provide gen-
eralized models that allow considering dif-
ferent stages of R&D project. Paper [Koussis, 
Martzoukos, Trigeorgis, 2007] elaborate the 
complex model that accounts for different 
conditions which company can face within 
its R&D process, for example, path-depend-
ence. [Schwartz, 2004]  proposes the model 
to value patents and licenses as real options. 
This model takes into account uncertainty 
of future cash flows as well as the possibil-
ity of abandoning the project. Classical 
modification of the Black–Scholes formula 
introduced in [Margrabe, 1978] was initial-
ly used to apply real options in IT industry. 
Later it proves itself being useful in R&D 
literature in the two-stage approach where 
efficiency of R&D projects implementation 
is taken into account. 
In this paper we consider one period R&D 
investment model dealing with the whole 
portfolio of real options of a company rath-
er than with each project separately. It will 
give the possibility of abstracting from di-
verse types of projects, package solutions, 
and strategic considerations, which act in 
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reality, delegating all responsibility for “op-
timal” decision to managers. It is assumed 
that management is able to maintain the 
portfolio in risk-neutral world defined in 
the terms of risk neutrality for sharehold-
ers. This is a  sophisticated skill. It is real-
istic to expect its validiy only for large pub-
lic (traded) companies, which are mature in 
their innovation practices. Risk-neutral 
probability is determined by stock price 
volatility since it is associated with custom-
ary shareholders’ risk. This gives us a pos-
sibility to use risk-neutral valuation without 
exact knowledge of internal decisions (it is 
impossible to formalize them!). Of course, 
each project lives in usual real world with 
its usual (frequency) probability but we deal 
with portfolio only. This is usual real op-
tions approach. We will return to further 
explanations in the next section. 
Our analysis is limited with large innova-
tion extensive companies. Only for such 
companies we can expect sophisticated man-
agerial skills mentioned above. Being trad-
ed in the stock market is also important to 
proceed with risk-neutral valuation (see 
Section 2 below). So, our model is not suit-
able, e. g., for startups or venture busi-
nesses, one of the traditional themes of R&D 
valuation. 
2. Model assumptions
The model proposed is based on the follow-
ing assumptions:
1. The model makes no distinction between 
different types of research projects that 
can be undertaken by a company. Thus, 
instead of considering separate projects, 
the model focuses on a  portfolio of re-
search projects. 
2. The single-period model is considered. 
In the moment t =  0 a  company starts 
many R&D projects and therefore al-
locates a  particular amount of money 
to them. Let us denote this quantity 
as RD. It is not known and should be 
determined within the model. In the 
moment t = T all R&D projects are fin-
ished and, as a  result, a  company may 
assess the prospects for business devel-
opment, if any, that stem from any 
chosen portfolio of projects.
3. Companies perform only those R&D ac-
tivities that can result in business de-
velopment (growth) and therefore derive 
additional value for shareholders. In 
other words, the main consequences of 
an R&D project are potential invest-
ments in real assets that are made at 
t  =  T as a  result of R&D. After R&D 
period performance is beyond the bor-
ders of our model.
4. We consider only mature and large com-
panies in R&D intensive industries. So 
we assume that each company has its 
own budget for potential investments, 
Inv, which does not fluctuate substan-
tially in time, hence, we can assume it 
is a known (deterministic) input in the 
model. Nevertheless, this parameter is 
unobservable since the set of accepted 
projects will need only some part of 
Inv. We will later call it actual volume 
of investment. Its value is observable 
and reported by the company. 
5. We also can assume that these companies 
follow a stable debt financing policy. So 
both R&D investments and real assets 
investments, which may follow, are fi-
nanced from equity and from debt in 
a  smooth way. It is enough to justify 
formula (8). For derivation of formula 
(12) we will impose an extra assumption 
of the use of operational profit as the 
only source of financing. 
6. The value of the company is identified 
with capitalization (it should be gross 
of dividends). As it is usual in financial 
economics we assume that the value fol-
lows Geometric Brownian Motion with 
volatility σ. Let us treat for simplicity 
the basic uncertainty as a  binary tree 
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in one period model (it is easy to gen-
eralize this approach to the general 
continuous case and then use the Black-
Scholes formula). So, if S is the value 
of company at t  =  0 then the value at 
t =  T is equal either
S Se S Seu
T
d
T
= =
−σ σor .  (1)
7. Portfolio of accepted R&D projects al-
lows a  company to invest the amount 
Inv in business development (launching 
of new products, development of tech-
nologies or business processes). These 
investments may lead to either value 
creation or value destruction.
8. We assume that volatility of return on 
value is the same as volatility of return 
on investments on any set of projects 
chosen by managers. So if company is 
ready to invest Inv but the choice of 
a portfolio of accepted projects will be 
done at time t =  T then the maximum 
value, which company is ready to spend 
for R&D, is equal to
RD Inv e T= −( )σ 1 .  (2)
To derive (2) we subtract expenses from 
the value of the portfolio estimated with the 
same growth rate as the company. Strictly 
speaking, only the part of Inv, which cor-
responds to accepted projects, will be actu-
ally invested. Let us recall that actual RD 
is now unknown and it will be determined 
as the main output of our model in the cause 
of real option analysis. We will add several 
other assumptions below.
3. Model for R&D expenses:  
company level
The decision on composition of a  portfolio 
of accepted R&D projects is a risky project, 
which we will analyze through the lenses of 
the real option analysis. 
Top managers and R&D department(s) 
should be able to decide for each combina-
tion of projects being included into portfo-
lio whether it adds or subtracts the value 
in the terms of risk-neutral behavior deter-
mined by basic uncertainty (1). If a  com-
pany has many projects, then different com-
binations should be tried. As a part of such 
choice both usual NPV considerations and 
many different advanced real options tech-
niques (see, e. g., [Childs, Triantis, 1999]) 
are used. Here we need our assumption of 
maturity, since only in a  mature company 
with a  lot of experience we can expect that 
its staff is able to maintain such a  sophis-
ticated task. Capitalization and its volatil-
ity are both easily observable by managers 
and important for investors. In these terms, 
it is often easier to convince the Board of 
Directors of the proposal. The problem of 
R&D projects selection was treated academ-
ically in [Cheung, Greenfield, Liao, 2009] 
where the issue of real options was also un-
der discussion.
Let us add some realistic details concern-
ing the portfolio formation. Not each project 
that adds value will be added, e. g., some-
times option to wait has higher value then 
given by (1). On the other hand, some follow-
up options may be accepted because of their 
future importance. Not only may the real 
options features of the projects be impor-
tant. For many advanced technologies elab-
orated by the companies there is not enough 
production capacity to produce the required 
innovative products. This case is known in 
the microprocessor industry. Direct invest-
ment in creating such capacity will dramat-
ically change the risk class of assets in place, 
so it is not expected. Many patents are not 
implemented in the production of medica-
tions by pharmaceutical companies. In high-
ly competitive industries many projects fail 
because rival companies could win the in-
novation race [Gu, 2016]. Of course, we can 
continue this line of observations further, 
but let us move to valuation setting. 
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It is known that some derivatives cannot 
be evaluated on the basis of risk-neutral 
probabilities. Robert Merton writes: “The 
validity of the classic Black–Scholes option 
pricing formula depends on the capability 
of investors to follow a  dynamic portfolio 
strategy in the stock that replicates the 
payoff structure to the option” [Merton, 
1976]. In the case of real options it is often 
not easy to construct tracking portfolio, 
since many real or intangible assets are not 
traded. In most cases it is very difficult (if 
possible at all) to assess their short sales 
for the purpose of arbitrage. For some pro-
jects it is possible sometimes to use out-
sourcing, licensing, and open innovation 
approaches to model nontraded assets but 
for general case we need more general con-
siderations. Our arguments are similar to 
the case of treating IT-investments as real 
options [Benaroch, Kauffman, 1999], which 
follow [Mason, Merton, 1985]. The last pa-
per claims that an arbitrageur can observe 
deviation of the company’s value from usu-
al company or industry trend. Here it is 
important that we assume all companies to 
be mature, i. e. their trends are known. Since 
we identify basic uncertainty with capitali-
zation, which is observable through trading, 
then this idea works directly.
So we are ready to formulate the follow-
ing important behavioral assumption:
9. Management team is able to evaluate 
and then choose portfolios of projects 
in the risk-neutral world for sharehold-
ers.
Denoting the risk-neutral probabilities 
as pu and pd we apply usual formulas [Hull, 
2012]:
p e e e e
p p
u
rT T T T
d u
= −( ) −( )
= −
− −σ σ σ/ ;
,1
 (3)
where r is risk-free rate. 
Hence, using formulas (2) and (3) we can 
assess the expected value, ,RD  of R&D out-
lays in the risk-neutral world: 
RD p RD p
Inv e e e
e e
u d
T rT T
T T
= + =
=
⋅ −( ) −( )
−( )
⋅ ⋅
−
−
0
1σ σ
σ σ
.
 (4)
Since the estimate of  RD in (3) is done 
assuming risk-neutrality, the amount of 
money RD0 that is equal to this expected 
value  RD  at t  =  0 can be computed ac-
cording to the following formula: 
RD RD e
Inv e e e e
e e
rT
rT T rT T
T T
0
1
= ⋅
=
⋅ −( ) −( )
−( )
=
−
− −
−
σ σ
σ σ
.
 (5)
The evaluation (5) is done in the risk-
neutral world. It can be interpreted in the 
following way. If the decision to make in-
vestments in real assets is made only after 
R&D activities are completed, then the 
maximum sum that a  company can afford 
to spend on R&D is RD0. Let us emphasize 
that it is just the value of managerial de-
cisions in accordance to the model. In real-
ity the investment may be a  failure at the 
stage of implementation, i. e., developing 
assets in place and sales. Nevertheless, the 
logic of the model still works. For example, 
in 2010s  mobile division of Nokia was in-
vesting intensively in R&D until the ac-
quisition by Microsoft in spite of the fact 
of dramatic decline in capitalization. 
It is noteworthy that Inv is the amount 
of potential investments, i. e., it is a  non-
observable variable that cannot be extract-
ed from companies’ financial reporting. In 
order to empirically test the model of R&D 
intensity, it is necessary to link the value 
RD0 with the amount of actually incurred 
investments, not with the amount of planned 
investments. Actually incurred investments, 
Invact, can be defined as Invact = Inv ⋅ pu and 
on the basis of (5) the following formula is 
derived:
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RD Inv e eact
T rT
0 1= ⋅ −( ) −σ . (6)
This formula shows the non-linear de-
pendence of R&D investment on σ and T. 
All three inputs are objective and observ-
able.
4. Model for R&D expenses:  
industry level
Undoubtedly, R&D expenditures depend not 
only on the propensity of management to 
conduct and finance R&D. Some large com-
panies that are industrial leaders have large 
R&D departments with unique equipment. 
Such companies can spend a  lot of money 
on R&D. The other large companies may 
have lower R&D expenditures because they 
prefer to buy patents or acquire small in-
novative companies. These costs will have 
different accounting treatment. That is why 
it is difficult to compare R&D expenditures 
of different companies, even though they 
belong to the same industry, because of va-
riety of specific factors. The current paper 
proposes a  model that does not contend to 
explain R&D expenditures of a  single com-
pany; instead, it can be used to explain in-
dustrial differences in R&D expenditures of 
large companies.
Moving on to the industrial level, it is 
necessary to average out R&D expenditures 
of all companies. Taking into consideration 
the R&D diversity across industries, we as-
sume that there is an average life-length of 
an R&D project that accounts for indus-
trial specifics ( )T . If so, (6) can be written 
as follows:
RD Inv e eind act ind
T rT
0 1; ;= ⋅ −( ) ⋅ −σ  (7)
where Invact; ind are actually incurred invest-
ments at the industrial level; σ  is typical 
volatility of value of a large company oper-
ating in a particular industry, T  is average 
life-length of R&D project in industry. The 
indicator RD0; ind represents itself single-
time expenses on financing all R&D projects 
within the period T .
It is assumed that companies do not at-
tract external financing for investments in 
real assets as a  result of an R&D project. 
For the sake of simplicity, the interest pay-
ments and taxes are not considered. Thus, 
theoretically companies may invest in assets 
the whole amount of their operating profit. 
Now it is the time to add the final as-
sumption (which is actually restrictive, see 
discussion in Section 6). 
10. The model assumes that the amount of 
investments in real assets is limited to 
operating profit that company receives 
in the period T .
Hence we get
Invact; ind =  OPan; ind ⋅ T , (8)
where OPan; ind is annual operating profit of 
all companies in the industry. Let us mention 
that the application of our logic to a  single 
company arrives to formula (8) for this com-
pany. But it reality operational profit of 
a  company may well be negative and equal-
ity does not make any sense. Our switch to 
the industry is partly related to this obser-
vation since overall operational profit of any 
industry considered is positive. 
In order to compare the model estimates 
with companies’ accounting data, let us as-
sume that R&D projects are financed uni-
formly throughout the period T :
RD T RDind an ind0; ;= ⋅ . (9)
Hence, it is possible to assume that (6) 
can be used to assess annual R&D expendi-
tures in the industry:
RD OP e ean ind an ind
T rT
; ;= ⋅ −( ) ⋅ −σ 1 . (10)
The commonly used indicator that allows 
comparing R&D activities of companies in 
different industries is R&D intensity indica-
,
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tor (RDI), which is defined (see [Baysinger, 
Hoskisson, 1989], for example) by the fol-
lowing formula: 
RDIind =  RDan; ind/Revan; ind, (11)
where RDIind are the annual R&D expendi-
tures and Revan; ind is annual revenue (sales).
By dividing both parts of (11) by revenue, 
the following expression is derived: 
RDI pm e eind ind
T rT
= ⋅ −( ) ⋅ −σ 1 , (12)
where pmind  =  OPan; ind/Revan; ind is average 
industrial profit margin.
As it is clear from (12), industrial RDI 
is determined by three main factors: average 
profit margin, average volatility of large 
companies’ value, and average life-length 
of an R&D project in a particular industry. 
The expression (12) will be henceforth re-
ferred to as the research model of the study.
5. Empirical validation
In order to empirically apply and test mod-
el (12), actual data on large companies from 
different developed countries (EU, USA, 
Canada, Japan, Israel and some others) 
were used. Data were retrieved from elec-
tronic dataset prepared for the European 
Commission report on industrial R&D in-
vestment [Hernández et al., 2017]. In doing 
so, we intended to test the model on the 
most recent data available. From the data-
base considered the information concerning 
companies’ revenue, operating margin and 
R&D expenditures was obtained.
The criteria of companies’ allocation to 
a  particular industry are mentioned in the 
report and we have not changed them. 
However, the following companies have been 
excluded from analysis: (1) companies from 
developing countries; (2) financial companies; 
(3) companies with annual revenue less than 
100 mln EUR. Additionally, we have exclud-
ed four industries with a  small number of 
large companies (less than 10). The resulting 
sample of 1833 companies from 25 industries 
was used. For each industry the following 
indicators were calculated:
•	 industrial R&D intensity as the ratio of 
R&D expenditures of all companies’ in 
a  particular industry to their total rev-
enue in 2016;
•	 industrial operating profit margin as the 
ratio of total operating profit of all com-
panies to their revenue.
One of the most difficult issues was the 
estimation of σ for different industries. 
These estimates cannot be derived from the 
dynamics of sectoral indices because in this 
case the values would be underestimated 
due to the effect of diversification. Hence, 
it is necessary to analyze the changes in 
value of the largest companies in the in-
dustry and then to average out the esti-
mates of σ . 
In the current paper the standard devia-
tion of large and medium US companies’ 
value from A. Damodaran website [Damo-
da ran, 2018] was taken as a  proxy of σ . 
The standard deviation in company value σ 
is computing with the following formula: 
σ σ σ
σ σ ρ
2 2
2
2
2
2 ,,
= ⋅ ( ) + ⋅ ( ) +
+ ⋅ ⋅ ⋅ ⋅ ⋅
E D
E D E D
E
V
D
V
E
V
D
V
 (13)
where E is equity value, D is debt value, 
V = E + D is company value, 2Eσ  and 
2
Dσ  are 
variances in equity value and debt value cor-
respondingly, and ,E Dρ  is correlation coef-
ficient between debt and equity.
The variance in debt value is tough to 
obtain, so A. Damodaran assumes that it is 
roughly 40% of the standard deviation of 
equity value (based upon the relative volatil-
ity in equity and bond indices) and that the 
correlation between stock and bond prices 
is 0.5 (again based upon the correlation be-
tween equity and bond indices). 
As justification for the choice of the stand-
ard deviation in company value as a  proper 
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estimate of σ in (12) it is possible to give 
following arguments. Despite the fact that 
companies can finance risky R&D projects, 
the model assumes that companies generally 
are willing to finance those R&D activities 
that have sound prospects for business. That 
is why it can be presumed that uncertainty 
of R&D results is consistent with the market 
estimate of uncertainty of a company’s value. 
For this reason, σ  can be assessed as a stand-
ard deviation of market value of a  company 
(that can be expressed in terms of stocks and 
debt volatility).
Table 1 shows the aggregated industrial 
data for the model verification. Since in 
database [Damodaran, 2018] the companies 
Table 1
Aggregated industrial data
Industry Number  of companies R&D intensity
Average 
industrial profit 
margin
σ
Aerospace & Defence 39 0.0426 0.0956 0.512
Automobiles & Parts 104 0.0483 0.0645 0.284
Chemicals 101 0.0347 0.1119 0.388
Construction & Materials 41 0.0108 0.0799 0.313
Electricity 17 0.0048 0.0809 0.156
Electronic & Electrical Equipment 168 0.0413 0.0811 0.497
Fixed Line Telecommunications 10 0.0161 0.1404 0.329
Food Producers 44 0.0143 0.1246 0.338
Gas, Water & Multiutilities 12 0.0051 0.0353 0.214
General Industrials 60 0.0339 0.0947 0.441
General Retailers 15 0.0108 0.0414 0.284
Health Care Equipment & Services 85 0.0329 0.0831 0.400
Household Goods & Home 
Construction
33 0.0222 0.1422 0.337
Industrial Engineering 156 0.0349 0.0773 0.454
Industrial Metals & Mining 22 0.0096 0.0435 0.488
Leisure Goods 31 0.0604 0.0734 0.354
Media 17 0.0313 0.0651 0.303
Mobile Telecommunications 12 0.0214 0.0310 0.227
Oil & Gas Producers 17 0.0044 0.0071 0.488
Personal Goods 35 0.0197 0.1310 0.359
Pharmaceuticals & Biotechnology 332 0.1666 0.1879 0.632
Software & Computer Services 222 0.1138 0.1630 0.460
Support Services 23 0.0364 0.1130 0.453
Technology Hardware & Equipment 223 0.0871 0.1446 0.438
Travel & Leisure 14 0.0160 0.1335 0.285
S o u r c e : computed by authors based on [Hernandez et al., 2017; Damodaran, 2018].
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are allocated to 94 industries, volatility 
data on some of them was aggregated to 
match the industries listed in the table. It 
is noticeable that σ  are significantly depend-
ent on industry: the estimates vary from 
16% to 63% in annual terms. 
The average life-length of R&D projects 
is difficult to assess for all industries. 
Anyway, in this empirical study we assume 
that the average life-length of R&D projects 
in different industries is taken as one year, 
i. e., T = 1 . Additionally we can add anoth-
er reason. Our mature companies run many 
projects simultaneously in a regular fashion. 
This regularity gives possibility to think that 
we can split entire R&D process in a rolling 
procedure with one year periods of analysis. 
In our calculations we ignore the risk-free 
rate, since it was close to 0 in the developed 
countries in 2016. 
It should be noted that industrial profit 
margin (pm) and volatility of companies’ 
value (σ) that are both included in (12) may 
not be independent.
6. Conclusions and further research
The treatment of R&D expenditures in the 
framework of real option analysis and re-
lated risk-neutral valuation depends on our 
main behavioral assumption 9. It is impos-
sible to justify the latter directly. Indirect 
verification can done through empirical anal-
ysis various versions of (6) where (8) is one 
of options. 
As a  very preliminary, and far from be-
ing sufficient, attempt for such justification 
we present the following consideration.
Fig.  1 demonstrates the results of com-
parison of RDI values assessed via (12) and 
actual RDI values retrieved from companies’ 
annual reports. The data were aggregated 
to the industrial level, so each dot on the 
graph represents a particular industry, with 
actual RDI going on the y-axis and modelled 
RDI going on the x-axis. If the model fitted 
the empirical data precisely, the modelled 
RDI are equal to actual RDI in each indus-
try, so all the dots would lay on a  straight 
line shown in Fig.  1.
The dashed line in Fig. 1 is the graph of the 
regression function with slope k^  = 1.11 and 
the coefficient of determination of R2 ≈ 0.71. 
The result obtained does not contradict to 
formula (12) and our suggestion that the 
model proposed can be used to explain in-
dustrial differences in R&D investment in 
large companies.
Now let us return to the general setting 
of the problem. Obviously not only volatil-
ity (as it is done in this work) and life-
length of R&D projects (as we intend to 
study along the same lines in the future) 
are relevant factors. The problem of taking 
in account heterogeneity is the goal of our 
future study.
The average life-length of R&D projects 
is difficult to assess for all industries. 
According to survey of companies’ managers 
[Whittard et al., 2009] and [Ker, 2013] the 
average life-length of R&D does not vary 
significantly across industries. An average 
technical R&D project in non-technological 
sectors lasts for 1.3  years, while in major 
technological sectors it lasts for 2 years (the 
largest life-length of 4.2 years is typical for 
chemical and pharmaceutical industries). 
In the meantime, the life-length of non-
technical R&D projects varies between 0.2 
and 0.8 years. Recent studies show that the 
life-length for drugs industry is much longer 
[PhRMA, 2015]. So, a lot of aggregation is 
needed here.
Financing from operational profit is a 
limitation of the current model. [David, 
O’Brien, Yoshikawa, 2008] provide deep 
analysis of R&D financing from debt. They 
suggest to distinguish between public and 
private debt where the first one is not an 
appropriate tool for investment in intangi-
bles whereas the second works well. Probably 
it will help to abandon the assumption of 
all-equity financing, which has been used in 
this paper.
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Fig. 1. The comparison of actual and modelled values of R&D intensity at the industrial level
Let us notice that the challenge of debt 
financing may be solved (at least theoreti-
cally) with sophisticated financial engineer-
ing. [Montazerhodjat, Frishkopf, Lo, 2016] 
consider new dynamic leverage instruments 
to maintain the debt optimally in the drug 
producing industry where the recent increase 
in expenditures is dramatic.
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Цель настоящей работы состоит в  разработке модели, которая может быть использована 
для оценки величины затрат на исследования и разработки крупных и зрелых компаний. 
Методология исследования основана на анализе реальных опционов. Затраты на иссле-
дования и разработки трактуются в модели как платежи по реальному опциону, который 
представляет собой право компании инвестировать в  будущем в  реальные активы и  тем 
самым обеспечивать развитие бизнеса. Основным результатом работы является модель 
оценки, которая включает в  себя несколько релевантных факторов. В  то время как в  су-
ществующих исследованиях подход на основе реальных опционов в  основном применя-
ется к  анализу отдельных проектов компаний или отдельных отраслей, в  настоящей 
статье данная методология используется для решения более общей задачи. Мы рассчи-
тываем на то, что результаты нашего исследования будут способствовать пониманию 
различной интенсивности исследовательской деятельности в  крупных инновационных 
компаниях.
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